drugset
drugset / Trial / NCT00655655

Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors

NCT00655655 ↗

Phase 1 Completed 96 enrolled Mayo Clinic
NaSingle-groupOpen-labelTreatment

Summary

RATIONALE: Everolimus and vatalanib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. Giving everolimus together with vatalanib may kill more tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of everolimus and vatalanib in treating patients with advanced solid tumors.

Timeline

Start
2004-12
Primary completion
2009-09-15
Completion
2018-01-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Everolimus Small molecule — Oral
Subject vatalanib Small molecule — Oral

Indications

PPoma cutaneous neuroendocrine carcinoma gastrin-producing neuroendocrine tumor glucagonoma medullary thyroid gland carcinoma melanoma non-small cell lung carcinoma pancreatic insulinoma pheochromocytoma renal cell carcinoma somatostatinoma